Eckert & Ziegler and Karlsruher Zyklotron AG Form a Strategic Alliance for the Production of Medical Radioisotopes

November 23, 2010

BERLIN, November 23, 2010 /PRNewswire-FirstCall/ — Eckert & Ziegler
Strahlen- und Medizintechnik AG (ISIN DE0005659700), a company specializing
in special compounds for the diagnosis and treatment of cancer, via its
subsidiary company Eckert & Ziegler f-con Deutschland GmbH closed an
exclusive sales agreement with the Karlsruhe-based ZAG Zyklotron AG for the
regular delivery of Fluorodeoxyglucose (18F) (FDG). FDG is used in the
context of the so called Positron Emission Tomography (PET) for the safe and
quick recognition of even the smallest tumour foci. Due to its short
half-life FDG has to be produced every day in cyclotrons and be delivered
freshly to the clinics. Moreover, Eckert & Ziegler acquired the option for
also producing and selling other radio-diagnostic products at the Karlsruhe

Eckert & Ziegler’s member of the Managing Board responsible for its
radiopharmaceuticals, Dr. Andre Hess, and Eckert & Ziegler’s f-con Managing
Director, Axel Schmidt, in a joint statement commented: “We are looking
forward to the closer co-operation with the Karlsruhe institution. It allows
us to more efficiently supply the south-western and southern regions of
Germany with short-lived radiopharmaceuticals and thus to further expand our
leading production and sales network in Germany. But we also plan to expand
our activities in adjacent territories, such as Poland. The peculiar thing
about the Karlsruhe institution, though, is that large amounts of production
capacities are available there and that the team there has a very broad
know-how in cyclotron technology.”

Eckert & Ziegler already operates several production sites for
radiopharmaceuticals in Germany and, besides Fluor-18-based radiodiagnostic
products for nuclear-medical imaging (PET), also markets the approved product
“Yttriga”, a precursor product of numerous radiotherapeutic products.
Moreover, Eckert & Ziegler provides synthesis technology and Gallium-68
radionuclide generator for nuclear-medical institutions worldwide.

For the current fiscal year the Board of Directors expects a turnover of
EUR 105 million and earnings per share of EUR 1.80 EUR. For the fiscal year
2011 earnings per share of EUR 2.00 EUR (excluding acquisitions) are

The long version of this press release is available at


In case of questions please contact:

Eckert & Ziegler AG, Karolin Riehle, Investor Relations,
Robert-Rossle-Str. 10, 13125 Berlin

Phone: +49(0)30-94-10-84-138,

Fax -112, email: karolin.riehle@ezag.de,


SOURCE Eckert & Ziegler AG

Source: newswire

comments powered by Disqus